Tyra Biosciences, Inc.
15.24+0.68 (+4.67%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · TYRA · USD
Key Stats
Market Cap
812.25MP/E (TTM)
-Basic EPS (TTM)
-1.79Dividend Yield
0%Recent Filings
8-K
First child dosed in trial
Tyra Biosciences kicked off the BEACH301 Phase 2 trial by dosing the first child with dabogratinib for achondroplasia on August 21, 2025. This pediatric study builds on adult data, targeting a rare growth disorder. Initial safety results are slated for the second half of 2026. Trial delays remain a key risk.
8-K
First SURF302 patient dosed
Tyra Biosciences dosed the first patient in its Phase 2 SURF302 trial of dabogratinib for FGFR3-altered intermediate-risk non-muscle invasive bladder cancer on August 14, 2025, advancing its FGFR3 franchise alongside the enrolling BEACH301 study in pediatric achondroplasia. Cash reserves stood at $296.3 million as of June 30, 2025, funding operations through at least 2027 despite a Q2 net loss of $28.1 million from ramped R&D costs. Pipeline momentum builds.
10-Q
Q2 FY2025 results
Tyra Biosciences ramped up R&D spending in Q2 FY2025 ended June 30, 2025, with expenses climbing 35% y/y to $24.3M from $18.0M, driven by clinical startups for BEACH301, SURF302, and SURF431 alongside headcount growth, while G&A rose 29% y/y to $7.1M on personnel costs. This pushed operating loss to $31.5M, up 34% y/y, and net loss to $28.1M or $(0.47) diluted EPS on 59.6M shares—worse than last year's $(0.32) but consistent with YTD trends showing no anti-dilution quirks. Cash burn quickened to $49.1M YTD from $32.3M, yet $296.3M in cash and marketable securities funds operations through 2027, bolstered by a fresh $150M ATM facility. No debt weighs on the balance sheet. Pipeline advances in FGFR programs look promising. Clinical trial delays pose a key risk.
8-K
First patient dosed in SURF302 trial
Tyra Biosciences kicked off the SURF302 Phase 2 trial on June 30, 2025, dosing the first patient with TYRA-300 for FGFR3-altered low-grade, intermediate-risk non-muscle invasive bladder cancer. This open-label study will enroll up to 90 participants across U.S. sites, randomizing them to 50 mg or 60 mg daily doses, with complete response at three months as the primary endpoint. Initial data readout is slated for the first half of 2026. Yet risks like enrollment delays loom large.
8-K
Annual meeting elects directors
Tyra Biosciences held its 2025 Annual Meeting on May 29, electing Todd Harris, Ph.D., Adele M. Gulfo, and S. Michael Rothenberg, M.D., Ph.D., as Class I directors for three-year terms, with strong support for Gulfo but notable withheld votes for the others. Shareholders overwhelmingly ratified Ernst & Young LLP as auditors for the fiscal year ending December 31, 2025. Governance continuity holds firm.
ATYR
aTyr Pharma, Inc.
0.94-0.03
AURA
Aura Biosciences, Inc.
6.14-0.23
ERAS
Erasca, Inc.
2.36-0.08
FBLG
FibroBiologics, Inc.
0.39-0.03
FBRX
Forte Biosciences, Inc.
14.38+0.92
KRRO
Korro Bio, Inc.
38.78-1.29
LYRA
Lyra Therapeutics, Inc.
5.83-0.12
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
TVRD
Tvardi Therapeutics, Inc.
4.78+0.06
VTYX
Ventyx Biosciences, Inc.
7.37-0.01